Patents Assigned to Allergan Botox Limited
-
Publication number: 20070269861Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 7, 2006Publication date: November 22, 2007Applicant: Allergan Inc., Allergan Botox LimitedInventors: James Williams, Bruce Thalley
-
Patent number: 6967088Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: GrantFiled: August 28, 1996Date of Patent: November 22, 2005Assignees: Allergan, Inc., Allergan Botox LimitedInventors: James A. Williams, Bruce S. Thalley
-
Publication number: 20050238665Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: November 30, 2004Publication date: October 27, 2005Applicant: Allergan, Inc., Allergan Botox LimitedInventor: James Williams
-
Publication number: 20040253673Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: December 16, 2004Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040235118Abstract: The present invention includes portions of soluble recombinant botulinum toxins. The invention also includes soluble fusion proteins which may comprise a portion of a botulinum toxin protein and a non-toxin protein sequence.Type: ApplicationFiled: December 4, 2003Publication date: November 25, 2004Applicant: Allergan, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040219637Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: November 4, 2004Applicant: Allergan Sales, Inc. Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040142455Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: July 22, 2004Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040115215Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: June 17, 2004Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20030219457Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: October 15, 2002Publication date: November 27, 2003Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20030215468Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: January 30, 2003Publication date: November 20, 2003Applicant: Allergan, Inc., Allergan Botox LimitedInventors: James A. Williams, Bruce S. Thalley